With a more convenient oral formulation, Novo can position itself as a competitor to traditional diabetes medications, such as metformin, sulfonylureas, and SGLT2 inhibitors that are taken by mouth
The future of this therapeutic class in IBD management depends on rigorous prospective trials, such as the COMMIT-CD program, to validate endoscopic healing endpoints and establish standardized protocols for monitoring clinical friction points
10.3389/fnins.2015.00092 Front
USFDA SENT WARNING LETTERS TO DRUGMAKERS INCLUDE LILLY, NOVO, HIMS & HERS COMPANIES
Phone Support Human Multiple phone lines are available: (609) 201-0119 for general customer service, (833) 322-7849 for additional support, and (609) 201-0114 for first-time medication orders